2014 ASH President Linda J. Burns, MD, of the University of Minnesota, offers her thoughts on abstract 379, “BLAST: A Confirmatory, Single-Arm, Phase II Study of Blinatumomab, a Bispecific T-Cell Engager (BiTE) Antibody Construct, in Patients with Minimal Residual Disease B-Precursor Acute Lymphoblastic Leukemia (ALL),” presented by Nicola Gökbuget, MD.
Time: 1:11
Laurie Sehn, MD, of the BC Cancer Agency, on abstract 629, “Brentuximab Vedotin Monotherapy in Diffuse Large B-Cell Lymphoma Patients With Undetectable CD30: Preliminary Results From a Phase II Study.”
2014 ASH President Linda J. Burns, MD, of the University of Minnesota, offers her thoughts on abstract 53, “ACE-536 Increases Hemoglobin and Decreases Transfusion Burden and Serum Ferritin in Adults With Beta-Thalassemia: Preliminary Results From a Phase II Study,” presented by Antonio G. Piga, MD.
Laurie Sehn, MD, of the BC Cancer Agency, on abstract 625, “Sustained Remission With the Combination Biologic Doublet of Lenalidomide Plus Rituximab as Initial Treatment for Mantle Cell Lymphoma: A Multicenter Phase II Study Report,” presented by Jia Ruan, MD, PhD.
Richard M. Stone, MD, of Dana-Farber Cancer Institute, offers his thoughts on abstract 6, "Sorafenib vs Placebo in Addition to Standard Therapy in Younger Patients With Newly Diagnosed Acute Myeloid Leukemia: Results from 267 Patients Treated in the Randomized Placebo-Controlled SAL-Soraml Trial," presented by Christoph Röllig, MD.
Bertrand Coiffier, MD, PhD, of Centre Hospitalier Lyon-Sud, offers his thoughts on abstract 393, “R-CHOP With or Without Radiotherapy in Nonbulky Limited-Stage Diffuse Large B-Cell Lymphoma: Preliminary Results of the Prospective Randomized Phase III 02-03 Trial from the Lysa/Goelams Group,” presented by Thierry Lamy, MD, PhD.
